Dexcom 

$74.65
332
+$2.29+3.16% Friday 20:00

統計

當日最高
74.73
當日最低
72.51
52週最高
142
52週最低
62.34
成交量
3,122,863
平均成交量
9,517,941
市值
29.91B
市盈率
47.25
股息收益率
-
股息
-

即將到來

收益

24Oct確認
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一個
0.14
0.26
0.38
0.5
預期每股收益
0.435085
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 DXCM 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

分析師評級

108$平均價格目標
最高估價為 $161。
來自過去 6 個月內的 15 個評級。這不是投資建議。
買入
67%
持有
33%
賣出
0%

關於

Health Technology
Medical Specialties
Manufacturing
Surgical and Medical Instrument Manufacturing
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Show more...
首席執行官
Kevin Sayer
員工
9500
國家
US
ISIN
US2521311074
WKN
000A0D9T1

上市公司